Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (AMA1-DiCo)
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial
Sponsor: BPRC
Listed as NCT02014727, this PHASE1 trial focuses on Malaria, Falciparum and remains completed. Sponsored by BPRC, it has been updated 11 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2019 — May 2020 [monthly]
Completed PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Completed PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BPRC
- Centre national de recherche et de formation sur le paludisme
- EVI Industries, Inc.
- Institut National de la Santé Et de la Recherche Médicale, France
- Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
For direct contact, visit the study record on ClinicalTrials.gov .